Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.[2][3]
History
The company was founded in 2007 as Genesis Biopharma. In 2013, Lion merged with Genesis Biopharma аnd became Lion Bio Pharma,[4] which was then rebranded to Iovance in 2017.[5]
In 2024, the US FDA gave accelerated approval to Lifileucel, marketed under the brand name Amtagavi. the company's tumor-infiltrating lymphocyte drug for the treatment of unresectable or metastatic melanoma.[6]. The company, which is currently trialing its TIL treatment for other cancers, released promising treatment response data for non-small cell lung cancer.[7]
See also
External links
References
- https://www.iovance.com/management/^
- Ken Garber. Pursuit of tumor-infiltrating lymphocyte immunotherapy speeds up Nature Biotechnology, 7 August 2019, retrieved 14 August 2019^
- Jacob Adelman. New Navy Yard lab and office complex planned for Calif. cell-therapy research firm Iovance The Philadelphia Inquirer, 29 May 2019, retrieved 14 August 2019^
- Genesis Biopharma completes merger with Lion Biotech www.thepharmaletter.com, retrieved 2026-03-10^
- Genesis Biopharma Announces Completion of Merger with Lion Biotechnologies www.businesswire.com, 2013-07-25, retrieved 2020-01-17^
- Asher Mullard. FDA approves first tumour-infiltrating lymphocyte (TIL) therapy, bolstering hopes for cell therapies in solid cancers Nature Reviews Drug Discovery, 2024-02-19^
- https://www.curetoday.com/view/amtagvi-prompts-responses-in-non-small-cell-lung-cancer^